Mark Ungs, President and CEO/Board Member
Mark Ungs recently served as the Vice President of New Business Development for Boston Scientific's multi-billion dollar Interventional Cardiology division where he was responsible for leading the division's growth outside its core businesses through internal development programs as well as external technology acquisitions into new therapies. Mr.Ungs has played key roles in launching the two largest commercial successes in the history of the medical device industry, the drug coated stent and cardiac resynchronization therapy for CHF, representing billions in incremental revenue for his employers.
In addition to InterValve, Mr. Ungs is the co-founder of ACTx, a startup that is developing a therapy that has the promise of redefining the science of tissue function recovery and regeneration.
Mr. Ungs has over twenty years professional experience in the medical device industry. He has a degree in Chemical Engineering from Oregon State University and an MBA from the University of California, Berkeley.
William Drasler, Chief Technology Officer
William Drasler has over 25 years professional experience in the medical device field. Mr. Drasler most recently held the position of VP of Applied Research at Boston Scientific where he directed leading edge development of cardiovascular devices and treatments for CHF, AMI, Stroke, and other clinically relevant problems. Dr. Drasler's experience includes VP of R&D for Possis Medical where he took the Angiojet thrombectomy project from inception through to production, VP of Engineering at Lake Region Manufacturing which manufactures guidewires and filters, and SciMed Life Systems where he worked on balloon bonding and balloon technology.
Dr. Drasler has over 30 major US patents issued and 14 patents pending. Dr. Drasler holds a MS in Chemical Engineering from UW Madison and a PhD in Biomedical Engineering from the University of Minnesota with research experience in fluid mechanics, blood rheology, and Sickle Cell disease.
Mr. Michael Berman is a medical device investor/entrepreneur who has co-founded 7 Medical Device companies and currently serves on the boards of 11 emerging medical device companies. From 1995-2000 Mr. Berman was the President of the Cardiology business of Boston Scientific. He has a BS and MBA from Cornell University. Mr. Berman currently serves of the boards of Aetherworks, AngioSlide, Apnex, Benechill, BridgePoint, Data Sciences International, Lutonix, MikrobEX, PharmaCentra and UltraShape.
Robert A. Van Tassel, M.D.
Dr. Robert Van Tassel received his undergraduate degree and Doctorate of Medicine from the University of Minnesota. He completed his residency in internal medicine at Hennepin County Medical Center in Minneapolis and a fellowship in cardiovascular medicine at the University of Minnesota. He served two years as a flight surgeon in the United States Air Force.
Dr. Van Tassel is a retired board certified cardiologist and served as a Senior Consultant in Cardiology at the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis and a Clinical Professor of Medicine at the University of Minnesota. He is a founder of the Minneapolis Heart Institute and past President of the Minneapolis Heart Institute Foundation.
Wes Pedersen, M.D., FESC, FACC, FSCAI,
Chief Medical Officer
Wes Pedersen, Chief Medical Officer is an Interventional Cardiologist at Minneapolis Heart Institute/Abbott Northwestern Hospital. Dr. Pedersen graduated from medical school at University of Washington in Seattle, and received his internal medicine training at the University of Minnesota Medical School/Hennepin County Medical Center where he also served as Chief Medical Resident. He is currently Director of the Percutaneous Valve Program at Minneapolis Heart Institute Foundation (MHIF) and Co-Director of the Cardiovascular Lab and Interventional Cardiology at Abbott Northwestern Hospital. He has formerly served as a Director of Research at Minneapolis Heart Institute Foundation, and he is currently Principal Investigator for various percutaneous valve trials including RADAR, Everest II, VIVID, PARTNER and REALISM.
For the past 19 years, he has had a well established, high volume practice treating high risk, elderly patients with aortic stenosis. He is well known nationally for his expertise in balloon aortic valvuloplasty. In April 2008, Dr. Pedersen successfully performed the first in man implant of a novel percutanous mitral valve repair device. He has published numerous articles in the catheter based management of aortic stenosis, and is a regular faculty participant at TCT, TVT, and ACC, presenting on various topics in the percutanous valve area, including BAV.
Dr. Paul Sorajja
Minneapolis Heart Institute® at Abbott Northwestern Hospital. Previously a professor of medicine at Mayo Clinic. Author of over 100 published manuscripts and book chapters. Dr. Sorajja's special interest is structural heart interventions, such as TAVR, balloon valvuloplasty, paravalvular leak repair and percutaneous valve implantation.
Irvin Goldenberg, M.D. FACC, FSCAI
Irvin Goldenberg, is a Board Certified Interventional Cardiologist who began doing BAV in the 1980s. He graduated from St Louis University School of Medicine. He received his internal medicine training at the University of Washington in Seattle and did his cardiology fellowship at the University of Minnesota. After his cardiology fellowship, he became the first Director of Research at the Minneapolis Heart Institute Foundation where he was a principal investigator or co-investigator for numerous national studies including 7 major NHLBI Cardiology Studies. He practiced as an interventional cardiologist at the Minneapolis Heart Institute from 1986 - 2000. Dr Goldenberg was chairman of the Abbott Northwestern Hospital Institutional Review Board (IRB) for 15 years (1995-2011). He also chaired the Allina IRB Executive Council. He currently is the Director of Research and President of the Twin Cities Heart Foundation. He has over 100 publications in peer reviewed medical journals and has written a book on Congestive Heart Failure.